CR2
Basic information
Region (hg38): 1:207453024-207489895
Links
Phenotypes
GenCC
Source:
- immunodeficiency, common variable, 7 (Moderate), mode of inheritance: AR
- common variable immunodeficiency (Supportive), mode of inheritance: AD
- immunodeficiency, common variable, 7 (Strong), mode of inheritance: AR
- systemic lupus erythematosus (Supportive), mode of inheritance: Unknown
- immunodeficiency, common variable, 7 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Common variable immune deficiency, 7 | AR | Allergy/Immunology/Infectious | Antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial | Allergy/Immunology/Infectious | 22035880 |
ClinVar
This is a list of variants' phenotypes submitted to
- Immunodeficiency,_common_variable,_7 (715 variants)
- Inborn_genetic_diseases (122 variants)
- not_provided (86 variants)
- CR2-related_disorder (35 variants)
- Systemic_lupus_erythematosus,_susceptibility_to,_9 (19 variants)
- Immunodeficiency,_common_variable,_2 (9 variants)
- not_specified (7 variants)
- Joubert_syndrome_17 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CR2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_001006658.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 178 | 188 | ||||
| missense | 367 | 33 | 405 | |||
| nonsense | 22 | 27 | ||||
| start loss | 0 | |||||
| frameshift | 20 | 26 | ||||
| splice donor/acceptor (+/-2bp) | 9 | |||||
| Total | 44 | 19 | 371 | 211 | 10 |
Highest pathogenic variant AF is 0.00088153355
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| CR2 | protein_coding | protein_coding | ENST00000367057 | 19 | 35666 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 4.74e-19 | 0.878 | 125652 | 0 | 94 | 125746 | 0.000374 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.793 | 542 | 597 | 0.909 | 0.0000315 | 7113 |
| Missense in Polyphen | 155 | 192.61 | 0.80474 | 2351 | ||
| Synonymous | -0.549 | 221 | 211 | 1.05 | 0.0000112 | 2151 |
| Loss of Function | 2.29 | 38 | 56.6 | 0.671 | 0.00000334 | 660 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000513 | 0.000510 |
| Ashkenazi Jewish | 0.0000997 | 0.0000992 |
| East Asian | 0.00141 | 0.00141 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.000405 | 0.000404 |
| Middle Eastern | 0.00141 | 0.00141 |
| South Asian | 0.000229 | 0.000229 |
| Other | 0.000328 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Receptor for complement C3Dd, for the Epstein-Barr virus on human B-cells and T-cells and for HNRNPU (PubMed:7753047). Participates in B lymphocytes activation (PubMed:7753047). {ECO:0000269|PubMed:7753047}.;
- Disease
- DISEASE: Immunodeficiency, common variable, 7 (CVID7) [MIM:614699]: A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. {ECO:0000269|PubMed:22035880}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Complement and coagulation cascades - Homo sapiens (human);B cell receptor signaling pathway - Homo sapiens (human);Hematopoietic cell lineage - Homo sapiens (human);Epstein-Barr virus infection - Homo sapiens (human);B Cell Receptor Signaling Pathway;Human Complement System;Dengue-2 Interactions with Complement and Coagulation Cascades;Oxidative Damage;Complement and Coagulation Cascades;Innate Immune System;Immune System;BCR;Regulation of Complement cascade;Complement cascade
(Consensus)
Recessive Scores
- pRec
- 0.458
Intolerance Scores
- loftool
- 0.952
- rvis_EVS
- 0.06
- rvis_percentile_EVS
- 57.56
Haploinsufficiency Scores
- pHI
- 0.134
- hipred
- N
- hipred_score
- 0.291
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.558
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | High | High | High |
| Primary Immunodeficiency | High | High | High |
| Cancer | High | High | High |
Mouse Genome Informatics
- Gene name
- Cr2
- Phenotype
- homeostasis/metabolism phenotype; immune system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype;
Gene ontology
- Biological process
- complement receptor mediated signaling pathway;immune response;complement activation, classical pathway;B cell differentiation;regulation of complement activation;B cell proliferation;innate immune response;viral entry into host cell
- Cellular component
- plasma membrane;integral component of membrane;receptor complex;extracellular exosome
- Molecular function
- virus receptor activity;complement binding;DNA binding;complement receptor activity;transmembrane signaling receptor activity;protein binding;protein homodimerization activity